-
-
-
-
-
-
-
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR)
-
-
-
-
-
-
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Misses Q1 EPS by 4c
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Tops Q3 EPS by 1c
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data
-
-
-
-
-
-
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
-
1,215,820 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

